COMMUNIQUÉS West-GlobeNewswire
-
Nordletics Makes Home Fitness Simple and Personalized
16/03/2026 -
Radiant Health Centers Announces CEO Transition
16/03/2026 -
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
16/03/2026 -
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
16/03/2026 -
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
16/03/2026 -
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
16/03/2026 -
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
16/03/2026 -
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
16/03/2026 -
Lucia Gaitan, M.D., FACOG, First in Miami to Offer Cerene® Endometrial Cryotherapy for Women with Heavy Periods
16/03/2026 -
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility
16/03/2026 -
Qolab Announces John Martinis Prize as Momentum Builds for Scalable Quantum Hardware
16/03/2026 -
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
16/03/2026 -
A Race Against Blindness Announces Spring 2026 Luxury Vehicle Fundraiser in Partnership with Foundation Fighting Blindness to Advance Pediatric Inherited Retinal Disease Research
16/03/2026 -
Completion of Share Buy-back Program
16/03/2026 -
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
16/03/2026 -
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
16/03/2026 -
4DMT to Participate in Upcoming Investor Meetings
16/03/2026 -
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
16/03/2026 -
Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
16/03/2026
Pages